Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston

Emerging drug targets at Discovery on Target 2026

Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website

53 organizations at Discovery on Target 2026 present work in emerging drug targets: 23 technology and service providers, 21 drug developers and 9 academic, government and non-profit bodies. Between them they bring 84 presentations to the program. Most represented: Pfizer (9 on the program), Genentech (7 on the program), Bristol Myers Squibb (4 on the program). As of Oct 8, 2026.

All 510 organizations at Discovery on Target 2026 →

Showing 1–8 of 53 organizations

Organization	Discovery on Target 2026 Attendance
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company developing medicines and vaccines in oncology, inflammation and immunology, internal medicine and rare diseases.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Emerging Drug Targets Talk Tue Sep 29 2:20pm–2:50pm Discovery of Potent and Brain-Penetrant Inverse Agonists for GPR61, an Orphan GPCR Emerging Drug Targets Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Panel Wed Sep 30 7:30am–8:15am Modern GPCR-Targeted Drug Discovery Lead Generation Strategies · with Computational Therapeutics Discovery Talk Wed Sep 30 11:50am–12:20pm A GIPR Small-Molecule Antagonist for Obesity Lead Generation Strategies Chair Wed Sep 30 2:00pm–2:05pm Chairperson's Remarks Lead Generation Strategies Talk Wed Sep 30 2:35pm–3:05pm Fragment Screening and Hit Optimization for an Orphan GPCR Using 19F-NMR and SPR Techniques Lead Generation Strategies Panel Thu Oct 1 7:30am–8:15am Building the Next Generation of DEL Datasets for AI Lead Generation Strategies Talk Thu Oct 1 9:35am–10:05am Extracting Actionable SAR from Primary DEL Screens to Drive Early Lead Optimization Lead Generation Strategies Talk Thu Oct 1 3:30pm–4:00pm Antibody-Drug Conjugate Immunogenicity: Current Landscape and Strategies to De-Risk Development Next-Generation Conjugates
Genentech South San Francisco, CA
gene.com Large pharma Biotechnology company and member of the Roche Group, discovering and developing medicines in oncology, immunology and neuroscience.	Talk Mon Sep 28 10:15am–10:45am AI-empowered Early Target Discovery with MARS: Multimodal Platform for Target Prioritization and Modality Selection Symposium: Generative AI/Machine Learning-Driven Drug Design Talk Tue Sep 29 11:05am–11:35am Molecular Basis of CXC Chemokine Receptor 3 Ligand Multispecificity Antibodies Against Challenging Targets Talk Wed Sep 30 12:20pm–12:50pm Template-Driven Scaffolding of SCFFBXO42 Regulates PP2A Degradation Emerging Drug Targets Talk Wed Sep 30 2:05pm–2:35pm Accelerating T Cell Engager Immunotherapy Discovery with High-Throughput Kinetic Multiparametric Platform Antibodies Against Challenging Targets Talk Thu Oct 1 11:50am–12:20pm Discovery of Novel Activators for Lysosome Ion Channel TMEM175, a Parkinson's-Disease Target Emerging Drug Targets Talk Thu Oct 1 4:05pm–4:35pm Using Metal Ions to Identify Novel PPI Binding Sites Lead Generation Strategies Talk Thu Oct 1 4:35pm–5:05pm Mechanistic Insights into Hit-Selection Based on DEL Screening Lead Generation Strategies
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global biopharmaceutical company with medicines in oncology, immunology, cardiovascular disease and neuroscience.	Talk Tue Sep 29 8:35am–9:05am Advancing KRAS G12C Active-State Inhibition through Next-Generation Covalent Warhead Design Lead Generation Strategies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Amgen, Novartis +3 more Novel drug modalitiesInnovative discovery technologies Panel Wed Sep 30 7:30am–8:15am Covalent Drug Design Strategies Lead Generation Strategies · with GSK Talk Thu Oct 1 12:20pm–12:50pm Direct-to-Biology Discovery of BMS-986526, an EP4 Agonist for the Treatment of Inflammatory Bowel Disease Lead Generation Strategies Talk Thu Oct 1 3:35pm–4:05pm Discovery of BMS-986196: A Brain-Penetrant, Covalent Inhibitor of Bruton’s Tyrosine Kinase (BTK) Emerging Drug Targets
Johnson & Johnson New Brunswick, NJ
jnj.com Large pharma Healthcare company whose Innovative Medicine segment, formerly Janssen, develops medicines in oncology, immunology and neuroscience.	Chair Tue Sep 29 8:30am–8:35am Chairperson's Remarks Emerging Drug Targets Panel Wed Sep 30 7:30am–8:15am Collaborative Conversations for Women in Science Plenary · with EMD Serono, Moderna Chair Wed Sep 30 9:00am–9:05am Chairperson's Remarks Novel Drug Modalities Talk Wed Sep 30 3:05pm–3:35pm Immunogenicity Mitigation for Biotherapeutics Discovery: Integrated Workflow of Tools and Assays for Diverse Modalities Innovative Discovery Technologies Panel Thu Oct 1 7:30am–8:15am Setting Up Collaborations & Partnerships Plenary · with Revolution Medicines
Broad Institute Cambridge, MA
broadinstitute.org Academic & healthcare Biomedical and genomic research institute in Cambridge, Massachusetts, founded by MIT and Harvard.	Talk Tue Sep 29 9:35am–10:05am From Genetic Validation to Lead Generation: Targeting the CARD9 Signalosome Emerging Drug Targets Talk Tue Sep 29 10:35am–11:05am Diverse Mechanisms of Small Molecule-Induced Protein Degradation Novel Drug Modalities Talk Wed Sep 30 3:05pm–3:35pm Protein Editing Using Proximity-inducing Molecules Novel Drug Modalities Talk Thu Oct 1 3:35pm–3:50pm Novel FGFR2 Biparatopic Antibodies for the Treatment of Cholangiocarcinoma Novel Drug Modalities
University of Michigan Ann Arbor, MI
	Talk Tue Sep 29 9:05am–9:35am Leveraging Structural Ensembles to Modulate the Function of RNAs in Cells Innovative Discovery Technologies Talk Tue Sep 29 10:35am–11:05am Development of Exceptionally Potent, Selective and Orally Active STAT6 Degraders Emerging Drug Targets Talk Wed Sep 30 2:05pm–2:35pm Targeting Gene Transcriptional Complexes by Domain Alteration Chimeras (DALTACs) Novel Drug Modalities Panel Thu Oct 1 7:30am–8:15am Scientific Work in the Age of AI Agents Innovative Discovery Technologies · with Montai Therapeutics, bPrescient
AbbVie North Chicago, IL
abbvie.com Large pharma Global biopharmaceutical company with medicines in immunology, oncology, neuroscience and aesthetics.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Lead Generation Strategies Talk Tue Sep 29 2:20pm–2:50pm Enhancing Small Molecule Lead Discovery with Ultra-High–Throughput Mass Spectrometry Lead Generation Strategies Chair Wed Sep 30 9:00am–9:05am Chairperson's Remarks Emerging Drug Targets
Yale University New Haven, CT
	Talk Mon Sep 28 9:15am–9:45am Enhancing Inhibition via Chemically Induced Proximity: A RIPTAC Targeting BCL6 and BET Proteins Symposium: Induced Proximity-Based Drug Discovery Talk Tue Sep 29 1:50pm–2:20pm Using DNA-Encoded Libraries to Discover Molecular Glues that bind FKBP12 and Structurally Distinct Targets Lead Generation Strategies Talk Wed Sep 30 3:35pm–4:05pm POSTER SPOTLIGHT: Development of CORTACs as a Small Molecule Strategy to Enhance Degrader Specificity Emerging Drug Targets